



US007618984B2

(12) **United States Patent**
Yamada et al.

(10) **Patent No.:** US 7,618,984 B2
(45) **Date of Patent:** Nov. 17, 2009

(54) **SULFONAMIDE COMPOUND**(75) Inventors: **Rintaro Yamada**, Tokyo (JP); **Minoru Seto**, Tokyo (JP)(73) Assignee: **Asahi Kasei Pharma Corporation**, Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 178 days.

(21) Appl. No.: **11/511,395**(22) Filed: **Aug. 29, 2006**(65) **Prior Publication Data**

US 2007/0179127 A1 Aug. 2, 2007

Related U.S. Application Data

(60) Provisional application No. 60/712,818, filed on Sep. 1, 2005.

(30) **Foreign Application Priority Data**

Aug. 30, 2005 (JP) 2005-248556

(51) **Int. Cl.****C07D 401/00** (2006.01)
A61K 31/47 (2006.01)(52) **U.S. Cl.** **514/309; 546/139**(58) **Field of Classification Search** None
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

4,798,897 A	1/1989	Hidaka et al.
5,081,246 A	1/1992	Hidaka et al.
5,216,150 A	6/1993	Hidaka et al.
5,245,034 A	9/1993	Hidaka et al.
2004/0102437 A1	5/2004	Takami et al.
2004/0138286 A1	7/2004	Imazaki et al.
2005/0020623 A1	1/2005	Yamada et al.
2005/0096310 A1	5/2005	Yamada et al.
2005/0272751 A1	12/2005	McKerracher et al.
2006/0079688 A1	4/2006	Shibuya et al.
2006/0167043 A1	7/2006	Iwakubo et al.
2006/0223829 A1	10/2006	Aertgeerts et al.
2006/0247266 A1	11/2006	Yamada et al.
2007/0088021 A1	4/2007	Hidaka et al.
2008/0021018 A1	1/2008	Ohshima et al.

FOREIGN PATENT DOCUMENTS

AU	20675/92 A	2/1993
EP	0 061 673 A1	10/1982
EP	0 287 696 A1	10/1988
EP	0 885 888 A1	12/1998
EP	0 956 865 A1	11/1999
EP	1 074 545 A1	2/2001
EP	1 541 151 A1	6/2005
EP	1 568 382 A1	8/2005
EP	1 878 732 A1	4/2006
EP	1 679 308 A1	7/2006
EP	1902731 A1	3/2008
EP	1905452 A1	4/2008

JP	57-156463 A	9/1982
JP	57-200366 A	12/1982
JP	62-111981 A	5/1987
JP	02-256666 A	10/1990
JP	4-264030 A	9/1992
JP	5-208973 A	8/1993
JP	6-100540 A	4/1994
JP	10-087491 A	4/1998
JP	2004-107335 A	4/2004
JP	2004-182723 A	7/2004
JP	2005-232175 A	9/2005
JP	2006-348028 A	12/2006
JP	2007-238458 A	9/2007
WO	WO-93/05014 A1	3/1993
WO	WO-97/23222 A1	7/1997
WO	WO97/28130 A1	8/1997
WO	WO98/06433 A1	2/1998

(Continued)

OTHER PUBLICATIONS

K. E. Kamm et al., *Annu. Rev. Physiol.* 1989, 51:299-313.


(Continued)

Primary Examiner—Zinna N Davis

(74) Attorney, Agent, or Firm—Birch, Stewart, Kolasch & Birch LLP

(57) **ABSTRACT**

A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G¹ represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G² represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G³ represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G⁴ represents hydroxyl group, or —N(R¹)(R²) (R¹ and R² represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, or a saturated heterocyclic group); G⁵ is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits phosphorylation of the myosin regulatory light chain.



(1)

13 Claims, No Drawings